missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human PDE3A (aa 1045-1139) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (73%), Rat (73%). This recombinant protein control fragment may be used for blocking experiments. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Cyclic nucleotide phosphodiesterases (PDEs) comprise a complex group of enzymes, and at least 5 major PDE families or classes with distinctive properties have been identified. Members of the cGMP-inhibited cAMP PDE (cGI-PDE) family, such as PDE3A, are characterized by high affinity for cAMP and cGMP and competitive inhibition of their cAMP hydrolytic activity by cGMP and certain positive inotropic agents (Meacci et al., 1992 [PubMed 1315035]).
Specifications
Specifications
| Accession Number | Q14432 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 5139 |
| Name | Human PDE3A (aa 1045-1139) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | A930022O17Rik; C87899; cAMP phosphodiesterase, myocardial cGMP-inhibited; CGI-PDE; CGI-PDE A; CGI-PDE-A; cGMP-inhibited 3',5'-cyclic phosphodiesterase A; cGMP-inhibited phosphodiesterase; cyclic GMP-inhibited phosphodiesterase A; cyclic nucleotide phosphodiesterase; HTNB; PDE3A; phosphodiesterase 3 A; phosphodiesterase 3 A, cGMP inhibited; phosphodiesterase 3 A, cGMP-inhibited; RNPDE3A |
| Common Name | PDE3A |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction